“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List – Biogen

1. “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Included in China’s Commercial Insurance Innovative Drug List  Biogen
2. Real-World Data Support for Lecanemab in Early AD  Medscape
3. Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at CTAD 2025  marketscreener.com
4. Breakthrough Alzheimer’s drug ‘could slow disease by 8 years’  Qazinform
5. Key facts: Biogen’s Alzheimer’s drug delays progression by 30%; CEO boosts shares  TradingView

Continue Reading